Jaguar Health Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
JAGX$0.44+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| (in thousands) · 2024 · 2023 | ||||
| Cash flows from operating activities | ||||
| Net comprehensive loss | $ | (29,057) | $ | (32,724) |
| Adjustments to reconcile net comprehensive loss to net cash used in operating activities: | ||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | 6,920 | 3,365 | ||
| Depreciation and amortization expenses | 1,422 | 1,511 | ||
| Stock-based compensation, vested and released restricted stock units, and exercised stock options | 1,269 | 1,535 | ||
| Amortization of operating lease - right-of-use-asset | 343 | 286 | ||
| Amortization of debt issuance costs, debt discount, and non-cash interest expense | 274 | 11,496 | ||
| Share in joint venture's loss | 78 | 42 | ||
| Shares issued in exchange for services | 9 | 166 | ||
| Gain on extinguishment of debt | (1,245) | (3,697) | ||
| Changes in assets and liabilities | ||||
| Accounts receivable | 718 | 205 | ||
| Other receivable | 160 | 417 | ||
| Inventory | (485) | (1,355) | ||
| Prepaid expenses and other current assets | (1,703) | (2,620) | ||
| Other assets | (331) | (20) | ||
| Accounts payable | (423) | (670) | ||
| Accrued liabilities | 65 | (3,428) | ||
| Deferred revenue | 765 | — | ||
| Operating lease liability | (337) | (300) | ||
| Total cash used in operating activities | (21,558) | (25,791) | ||
| Cash flows from investing activity | ||||
| Purchase of equipment | (16) | — | ||
| Total cash used in investing activity | (16) | — | ||
| Cash flows from financing activities | ||||
| Proceeds from issuance of shares in At the Market offering, net of issuance and offering costs of $127 and $177 in 2024 and 2023, respectively | 27,759 | 20,847 | ||
| Proceeds from issuance of common shares in exchange for License Agreement | 1,150 | — | ||
| Payment of Tempesta Note | (100) | (50) | ||
| Repayment of insurance financing | (437) | (293) | ||
| Investment from noncontrolling interest | — | 1,227 | ||
| Proceeds from issuance of warrants in PIPE financing | — | 1,235 | ||
| Proceeds from issuance of preferred stock in PIPE financing, net of issuance and offering costs of $12 | — | 611 | ||
| Total cash provided by financing activities | 28,372 | 23,577 | ||
| Effects of foreign exchange rate changes on assets and liabilities | 2 | (29) | ||
| Net increase (decrease) in cash | 6,800 | (2,243) | ||
| Cash at beginning of the year | 6,469 | 5,469 | ||
| Cash at end of the year | $ | 13,269 | $ | 3,226 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)
| Nine Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2024 · 2023 | ||||
| Supplemental schedule of cash flow information | ||||
| Cash paid for interest | $ | 14 | $ | 23 |
| Supplemental schedule of non-cash financing and investing activities | ||||
| Common stock issued to Iliad in exchange for notes payable and accrued interest | $ | 4,906 | $ | 1,275 |
| Preferred stock issued to Streeterville in exchange for notes payable and accrued interest | $ | 4,485 | $ | 1,730 |
| Common stock issued to Streeterville in exchange for Series J Preferred Stock | $ | 1,999 | $ | — |
| First Insurance Financing | $ | 519 | $ | — |
| Recognition of operating lease - right-of-use asset and operating lease liability | $ | 219 | $ | 30 |
| Common stock issued to Streeterville in exchange for notes payable and accrued interest | $ | 166 | $ | — |
| Umbrella Insurance Financing | $ | 52 | $ | 93 |
| Preferred stock issued to Irving in exchange of notes payable and accrued interest | $ | — | $ | 2,201 |
| Common stock issued to Irving in exchange of notes payable and accrued interest | $ | — | $ | 2,022 |
| Warrants issued to Irving in exchange of Standstill | $ | — | $ | 1,934 |
| Warrants issued to Iliad in exchange of Standstill | $ | — | $ | 535 |
| Warrants issued to Irving due to Royal Interest Global Amendment | $ | — | $ | 60 |
| Warrants issued to Streeterville due to Royal Interest Global Amendment | $ | — | $ | 59 |
| Warrants issued to Iliad due to Royal Interest Global Amendment | $ | — | $ | 54 |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.